Pfizer (PFE), Astellas Pharma Inc. Reports Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. today announced that the Phase 3 ARCHES trial evaluating XTANDI® (enzalutamide) plus androgen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
